What the FDA labels say about taking them together
Gemfibrozil and selexipag
Gemfibrozil's FDA label of April 10, 2026 names selexipag in its contraindications section, and selexipag's label names gemfibrozil too. The gemfibrozil label: “Co-administration of gemfibrozil with selexipag doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold.”
Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the selexipag FDA label on DailyMed (effective May 28, 2026, Actelion Pharmaceuticals US, Inc.).
What does the gemfibrozil label say about selexipag?
Gemfibrozil label, contraindicationsCombination therapy of gemfibrozil with selexipag (see PRECAUTIONS ).
Gemfibrozil label, drug interactionsCo-administration of gemfibrozil with selexipag doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold.
Source: FDA drug label (Lopid, NDA018422), Parke-Davis Div of Pfizer Inc, effective May 21, 2026 (SPL set c48855b7-215e-453b-b3b1-a0f9dee7221f), via openFDA
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
What does the selexipag label say about gemfibrozil?
Selexipag label, contraindicationsConcomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil) [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
Selexipag label, drug interactionsConcomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled the exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold.
Source: FDA drug label (UPTRAVI), Actelion Pharmaceuticals US, Inc., effective May 28, 2026 (SPL set a7a23b87-f892-4e2c-8e2e-ebf841220f90), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gemfibrozil | Selexipag | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | Pulmonary arterial hypertension |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.104 per tablet 600 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once